TRAIL R1

TRAIL R1

TRAIL R1 Overview

Molecule Name
Tumor necrosis factor receptor superfamily member 10A
Synonyms
TNFRSF10A,TRAIL-R1,CD261,APO2,DR4
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs1
Highest Development StageApproved
Target Synonym
TRAIL-R1,Tumor necrosis factor receptor superfamily member 10A,DR4,TRAILR1,APO2,TNFRSF10A,TNF Receptor Superfamily Member 10a,Tumor Necrosis Factor Receptor Superfamily, Member 10a,Death Receptor 4,TRAIL Receptor 1,Cytotoxic TRAIL Receptor,CD261 Antigen,TRAILR-1,CD261,TNF-related apoptosis-inducing ligand receptor 1,Tumor Necrosis Factor Receptor Superfamily Member 10a Variant 2
Background
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) is also known as TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), Death receptor 4 (DR4), CD261 and APO2, which belongs to TNF superfamily. TRAILR1 / TNFRSF10A contains 1 death domain and 3 TNFR-Cys repeats. TNFRSF10A / DR4 is widely expressed and high levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells. APO2 / TNFRSF10A is receptor for the cytotoxic ligand TNFSF10 / TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TRAILR-1 / DR4 / CD261 promotes the activation of NF-kappa-B.

TRAIL R1 Product List

Species
  • Human(2)
Tag
  • Fc Tag(1)
  • His Tag(1)
Host
  • HEK293(2)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • No(2)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
TRAIL R1
Human TRAIL R1 / DR4 / TNFRSF10A Protein, His Tag
Human
HEK293
SDS-PAGE
ELISABLI

$285.00

100ug
TRAIL R1
Human TRAIL R1 / DR4 / TNFRSF10A Protein, Fc Tag
Human
HEK293
SDS-PAGE
ELISABLI

$285.00

100ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Dulanermin (Shanghai GeBaiDe)Phase 3 ClinicalShanghai Gebaide Biotechnology Co Ltd
Carcinoma, Non-Small-Cell Lung
Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech)Phase 3 ClinicalShenzhen Sinobioway Xinpeng Biomedicine Co Ltd
Neoplasms
Details
HLX56HLX56; HLX-56Phase 1 Clinical
Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
AponerminApprovedBeijing Shadong Biotech Co Ltd沙艾特, ShaiteMainland ChinaMultiple MyelomaWuhan Hiteck Biological Pharma Co Ltd2023-11-02
Multiple Myeloma
Details
Customer Reviews